Eli Lilly announced the launch of Trulicity ... RELATED: Trulicity Pen Approved for Type 2 Diabetes. Trulicity is available as 0.75 and 1.5mg single-use pens in 4-count cartons.

Eli Lilly and Company's (NYSE: LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind.

Some of the Trulicity app’s features include medication reminders, a virtual demo of the Trulicity pen, live chats to answer questions in real-time, videos, and access to a savings card. To have a ...

Eli Lilly and Company announced that the FDA granted approval to two higher doses, 3 mg and 4.5 mg, of its GLP-1 receptor agonist, Trulicity. The approval was based on data from the AWARD-11 phase ...

INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...

Eli Lilly has launched its once-weekly diabetes therapy Trulicity in the US, hoping to break into the fast growing, competitive GLP-1 agonist market. Trulicity (dulaglutide) was approved by the FDA at ...

(RTTNews) - Eli Lilly and Co. (LLY) said that the label for once-weekly Trulicity or dulaglutide is now updated to include use in combination with basal insulin for adults with type 2 diabetes ...

The Food and Drug Administration (FDA) has approved Trulicity (dulaglutide; Eli Lilly) pen as adjunct to diet and exercise to improve glycemic control in in adults with type 2 diabetes.

Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) ... It is now available to patients in 0.75 mg and 1.5 mg doses, delivered in the single-dose Trulicity pen.